Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases
- Conditions
- Dendritic Cell -Mediated Rheumatic Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 73
- Registration Number
- NCT04948099
- Locations
- 🇵🇱
ARS RHEUMATICA Sp. z o.o. REUMATIKA-Centrum Reumatologii NZOZ, Warsaw, Mazowieckie, Poland
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Altoona Clinical Research, Duncansville, Pennsylvania, United States
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT04933695
- Locations
- 🇺🇸
Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Northport Veterans Affairs Medical Center, Northport, New York, United States
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT04887064
- Locations
- 🇺🇸
Pinnacle Clinical Research - San Antonio, San Antonio, Texas, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 23
- Registration Number
- NCT04885998
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇦🇹Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, Austria
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 47
- Registration Number
- NCT04857606
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸ProSciento Incorporated, Chula Vista, California, United States
🇺🇸The Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: Tezepelumab Dose 1Biological: PlaceboBiological: Tezepelumab Dose 2
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 183
- Registration Number
- NCT04833855
- Locations
- 🇺🇸
Jonathan Corren MD Inc, Los Angeles, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇨🇦Gordon Sussman Clinical Research Incorporated, North York, Ontario, Canada
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT04825678
- Locations
- 🇺🇸
Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3
- Registration Number
- NCT04822298
- Locations
- 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, Austria
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria
🇦🇺Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- Conditions
- Active Juvenile Psoriatic Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT04804553
- Locations
- 🇬🇧
Nottingham Childrens Hospital, Nottingham, United Kingdom
🇮🇹Ospedale Santissima Annunziata, Chieti, Italy
🇦🇹Landeskrankenhaus Bregenz, Bregenz, Austria
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
- Conditions
- Uncontrolled Gout
- Interventions
- Biological: Pegloticase
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 11
- Registration Number
- NCT04772313
- Locations
- 🇺🇸
Providence St. John's Health Clinic, Santa Monica, California, United States
🇺🇸IRIS Research and Development, LLC, Plantation, Florida, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States